# Sexual health interventions for treating sexual dysfunction in women with female genital mutilation: A systematic review

**Authors:** Uduak Okomo, Chioma Oringanje, Miriam Nwaneri‐Ogugbue, Elizabeth Inyang, Babatunde Okusanya, Petra‐Favour Okoh, Mavis Otonkue, Martin Meremikwu

PMC · DOI: 10.1002/ijgo.70761 · International Journal of Gynaecology and Obstetrics · 2026-01-26

## TL;DR

This review examines non-surgical treatments for sexual dysfunction in women with female genital mutilation, finding limited evidence but some promise with a specific device combined with therapy.

## Contribution

The study provides the first systematic review of non-surgical interventions for sexual dysfunction in women with FGM.

## Key findings

- The Eros-Clitoral Therapy Device combined with psychotherapy improved sexual function in women with Type I FGM.
- Evidence for non-surgical interventions is limited to a single small trial and cannot be generalized to other FGM types.
- More research is needed to understand the safety and effectiveness of interventions across diverse FGM types and populations.

## Abstract

Female sexual dysfunction (FSD), characterized by persistent problems with desire, arousal, orgasm, or pain, can occur in women with any type of female genital mutilation (FGM) as a result of anatomical changes, pain, or psychological trauma.

To systematically review the evidence on the effects of non‐surgical interventions, including sexual counseling, mechanical devices, and lubricants, on the sexual function in women living with FGM.

A comprehensive search was conducted in CINAHL Plus, IRIS, MEDLINE (Ovid), PsycINFO (EBSCOhost), SCOPUS, and Web of Science from inception to November 2025. Reference lists were hand‐searched and study authors contacted for additional data.

Studies were eligible if they involved women with any type of FGM who received non‐surgical interventions for FSD.

One controlled trial met the inclusion criteria. Data were extracted independently by two reviewers, and the certainty of the evidence was assessed using the GRADE approach.

In women with Type I FGM, use of the FDA‐approved Eros‐Clitoral Therapy Device (CTD) combined with psychotherapy led to statistically significant improvements across all domains of the Female Sexual Function Index compared with psychotherapy alone. In the control group, only orgasm scores improved.

Evidence on non‐surgical interventions for FSD in women with FGM is extremely limited and based solely on a small single trial in women with Type I FGM. Although Eros‐CTD shows promise, findings cannot be generalized to other FGM types, and data on safety and contraindications are lacking. Further research is needed across diverse populations and FGM types to inform practice and policy.

## Full-text entities

- **Diseases:** bladder or bowel disorders (MESH:D001745), CTD (MESH:D009471), stroke (MESH:D020521), Type I FGM (MESH:D005833), infection (MESH:D007239), vulvodynia (MESH:D056650), FSD (MESH:D012735), dyspareunia (MESH:D004414), trauma (MESH:D014947), intimate (MESH:C563733), cervical cancer (MESH:D002583), FGM (MESH:D005831), diabetic (MESH:D003920), arousal and orgasm disorders (MESH:D020018), metastases (MESH:D009362), sexual disease (MESH:D012749), spinal cord injury (MESH:D013119), anxiety (MESH:D001007), vulvar or clitoral pain (MESH:D014845), sexual (MESH:D050035), hematoma (MESH:D006406), allergic (MESH:D004342), skin irritation (MESH:D012871), Pain (MESH:D010146), multiple sclerosis (MESH:D009103), arousal disorder (MESH:D020921)
- **Chemicals:** CTD (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12833628/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12833628/full.md

## References

42 references — full list in the complete paper: https://tomesphere.com/paper/PMC12833628/full.md

---
Source: https://tomesphere.com/paper/PMC12833628